主 办:北 京 中 医 药 大 学
ISSN 1006-2157 CN 11-3574/R

JOURNAL OF BEIJIGN UNIVERSITY OF TRADITIONAL CHINE ›› 2018, Vol. 41 ›› Issue (11): 905-909.doi: 10.3969/j.issn.1006-2157.2018.11.005

Previous Articles     Next Articles

Intervention to PI3K/AKT signaling pathway by Buqi Huoxue Tongluo Fang in rats with idiopathic pulmonary fibrosis*

Zhang Yanxia, Shi Liqing#, Yang Xiaohua, Shi Lei   

  1. Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China
  • Received:2018-05-20 Online:2018-11-30 Published:2018-11-30
  • Supported by:
    National Natural Science Foundation of China (No. 81603577)

Abstract: Objective To investigate the influence of Buqi Huoxue Tongluo Fang (Qi-tonifying Blood-activating Collateral-freeing Formula, BHTF) on PI3K/AKT signaling pathway in rat model of idiopathic pulmonary fibrosis (IPF). Methods All rats were randomly divided into 6 groups including normal group, model group, prednison group, low-dose, mid-lose and high-dose BHTF groups. Except of normal group, other groups were given bleomycin (3 mg/kg) for modeling. After 2 d, all BHTF groups were orally given BHTF decoction in different doses (8.25 g/kg, 16.5 g/kg and 33 g/kg), prednison group was orally given prednisone acetate suspension (3.6 mg/kg), and normal group and model group were orally given equivalent normal saline. The changes of rat general status were observed, difference in protein expressions of PTEN, PI3K, AKT and mTOR signaling pathway were detected by using immunohistochemistry technique, and difference in genetic expressions was observed by using RT-PCR at 2 time points (14 d and 28 d). Results Compared with model group and prednison group, the rat general status and weight were improved (P<0.05), PTEN expression was up-regulated and expressions of PI3K, AKT and mTOR were down-regulated in all BHTF groups (P<0.05). Conclusion BHTF can play an anti-fibrosis role through intervening the activation of PI3K/AKT signaling pathway.

Key words: Buqi Huoxue Tongluo Fang (Qi-tonifying Blood-activating Collateral-freeing Formula), idiopathic pulmonary fibrosis, PI3K/AKT signalingpathwag, mTOR, rats

CLC Number: 

  • R285.5